# Clinical Cases: COVID-19: Immunological, Vascular, and Infectious Disease Perspectives

## Case 1: Severe COVID-19 with Cytokine Storm

### Clinical Image
![CT chest showing bilateral ground-glass opacities and consolidation in severe COVID-19 pneumonia with cytokine storm](case_01_image.jpg)
*Source: [Wikipedia - Cytokine storm](https://en.wikipedia.org/wiki/Cytokine_storm) - CC BY-SA 4.0*

### Case Presentation
A 58-year-old male with type 2 diabetes mellitus (HbA1c 8.9%) and obesity (BMI 34) presents to the emergency department with 8 days of progressive dyspnea, dry cough, and fever up to 39.8C. He tested positive for SARS-CoV-2 by rapid antigen 6 days ago and initially managed symptoms at home with acetaminophen. Over the past 48 hours, he developed worsening hypoxia requiring supplemental oxygen. On examination, he is tachypneic (RR 32/min), tachycardic (HR 118 bpm), febrile (39.4C), and hypoxic (SpO2 82% on room air). Bilateral crackles are auscultated to the mid-lung fields. Chest CT reveals diffuse bilateral ground-glass opacities with areas of consolidation. Laboratory studies reveal markedly elevated IL-6 (342 pg/mL; normal <7), ferritin (2,840 ng/mL), CRP (218 mg/L), D-dimer (4.2 mcg/mL FEU), LDH (612 U/L), and lymphopenia (absolute lymphocyte count 0.4 x 10^9/L). Troponin I is mildly elevated at 0.08 ng/mL. He is admitted to the ICU, initiated on high-flow nasal cannula at 60 L/min with FiO2 0.90, dexamethasone 6 mg IV daily, and tocilizumab 8 mg/kg IV for refractory hyperinflammation. Remdesivir 200 mg IV loading dose followed by 100 mg daily is started. Despite intervention, he requires intubation on hospital day 3 with P/F ratio of 88, consistent with severe ARDS.

### Key Learning Points
- Delayed type I interferon (IFN-alpha/beta) responses in severe COVID-19 permit unchecked viral replication during the first week, leading to a compensatory hyperinflammatory cascade characterized by excessive IL-6, TNF-alpha, and IL-1beta release from activated macrophages and monocytes
- Cytokine storm in COVID-19 is driven by a maladaptive innate immune response: impaired plasmacytoid dendritic cell IFN production combined with inflammasome activation (NLRP3) and pyroptosis of infected cells amplifies systemic inflammation
- Lymphopenia (particularly CD4+ and CD8+ T cell depletion) is a hallmark of severe disease and correlates with impaired viral clearance, creating a vicious cycle of viral persistence and immune hyperactivation
- Dexamethasone reduces 28-day mortality in patients requiring supplemental oxygen (RECOVERY trial), while tocilizumab (anti-IL-6 receptor) provides additional benefit in patients with rapidly escalating oxygen requirements and elevated inflammatory markers

---

## Case 2: COVID-19-Associated Pulmonary Embolism

### Clinical Image
![CT pulmonary angiography showing bilateral pulmonary emboli with right heart strain](case_02_image.jpg)
*Source: [Wikipedia - Pulmonary embolism](https://en.wikipedia.org/wiki/Pulmonary_embolism) - CC BY-SA 4.0*

### Case Presentation
A 47-year-old female nurse presents to the emergency department on day 10 of symptomatic COVID-19 with sudden-onset pleuritic chest pain, hemoptysis, and worsening dyspnea. She had been managing mild-to-moderate symptoms at home and was not on prophylactic anticoagulation. She has no prior history of VTE, is on combined oral contraceptive pills, and has a BMI of 29. Vital signs reveal HR 124 bpm, BP 98/62 mmHg, RR 28/min, SpO2 88% on room air, and temperature 37.8C. Examination reveals a right ventricular heave, distended jugular veins, and an accentuated P2. ECG shows sinus tachycardia, right axis deviation, S1Q3T3 pattern, and T-wave inversions in V1-V4. Laboratory studies demonstrate D-dimer >20 mcg/mL FEU, troponin I 0.52 ng/mL, BNP 680 pg/mL, and lactate 3.8 mmol/L. CT pulmonary angiography reveals bilateral saddle pulmonary emboli with right ventricular dilation (RV/LV ratio 1.4). Bedside echocardiography confirms right ventricular dysfunction with McConnell sign. Given the submassive PE with hemodynamic compromise, she receives unfractionated heparin bolus 80 units/kg followed by 18 units/kg/hr infusion. Interventional radiology performs catheter-directed thrombolysis with alteplase 1 mg/hr over 12 hours per catheter, with subsequent hemodynamic improvement.

### Key Learning Points
- SARS-CoV-2 triggers immunothrombosis through multiple mechanisms: direct endothelial infection via ACE2 receptors causes endotheliitis, complement activation (C5a, MAC) damages the vascular endothelium, and activated neutrophils release neutrophil extracellular traps (NETs) that serve as scaffolding for thrombus formation
- COVID-19 produces a prothrombotic state with elevated factor VIII, von Willebrand factor, and fibrinogen, alongside suppressed fibrinolysis due to elevated plasminogen activator inhibitor-1 (PAI-1), creating a net procoagulant milieu distinct from classic DIC
- The incidence of VTE in hospitalized COVID-19 patients ranges from 20-30% even with standard prophylactic anticoagulation, justifying intermediate- or therapeutic-dose thromboprophylaxis in critically ill patients
- Markedly elevated D-dimer (>4x upper limit of normal) in COVID-19 is an independent predictor of mortality and should prompt aggressive evaluation for thromboembolic complications

---

## Case 3: Multisystem Inflammatory Syndrome in Children (MIS-C)

### Clinical Image
![Child with bilateral non-exudative conjunctival injection and polymorphous rash consistent with MIS-C](case_03_image.jpg)
*Source: [Wikipedia - Multisystem inflammatory syndrome in children](https://en.wikipedia.org/wiki/Multisystem_inflammatory_syndrome_in_children) - CC BY-SA 4.0*

### Case Presentation
A 7-year-old previously healthy male presents with 5 days of persistent high fever (40.2C), diffuse abdominal pain with vomiting and diarrhea, a polymorphous erythematous rash on the trunk and extremities, bilateral non-exudative conjunctival injection, and cracked erythematous lips. His parents report he had a mild upper respiratory infection 4 weeks ago that resolved without treatment; no COVID-19 testing was performed at that time. On examination, he appears toxic with HR 142 bpm, BP 78/48 mmHg (hypotensive for age), RR 30/min, and SpO2 95% on room air. There is diffuse abdominal tenderness without peritoneal signs, bilateral cervical lymphadenopathy (>1.5 cm), and palmar erythema with early desquamation of the fingertips. Laboratory studies reveal CRP 285 mg/L, ESR 82 mm/hr, ferritin 1,450 ng/mL, D-dimer 6.8 mcg/mL FEU, fibrinogen 680 mg/dL, procalcitonin 12.4 ng/mL, troponin I 0.34 ng/mL, BNP 2,400 pg/mL, albumin 2.1 g/dL, sodium 128 mEq/L, and lymphopenia (ALC 0.6 x 10^9/L). SARS-CoV-2 nucleocapsid antibody is positive, confirming prior infection. Echocardiography reveals mildly dilated left anterior descending coronary artery (Z-score +2.8) with reduced ejection fraction of 38%. He is admitted to the pediatric ICU, started on IV immunoglobulin 2 g/kg over 12 hours, methylprednisolone 2 mg/kg/day, aspirin 3-5 mg/kg/day for coronary involvement, and norepinephrine for fluid-refractory shock.

### Key Learning Points
- MIS-C is a post-infectious hyperinflammatory syndrome occurring 2-6 weeks after SARS-CoV-2 infection, driven by a superantigen-like motif on the SARS-CoV-2 spike protein that cross-links TCR V-beta regions with MHC class II, causing polyclonal T cell activation and massive cytokine release
- The clinical overlap with Kawasaki disease (conjunctivitis, mucosal changes, rash, coronary artery involvement) reflects shared downstream pathways of immune-mediated vasculitis, but MIS-C is distinguished by older age at presentation, more prominent cardiac dysfunction/shock, and gastrointestinal involvement
- Coronary artery aneurysms in MIS-C are monitored by serial echocardiography using Z-scores; aneurysms with Z-score >2.5 warrant antiplatelet therapy, while giant aneurysms (Z-score >10) require anticoagulation
- IVIG works by Fc receptor blockade, anti-idiotypic antibody effects, and modulation of complement activation, while corticosteroids suppress NF-kB-mediated transcription of proinflammatory cytokines

---

## Case 4: Paxlovid Drug Interaction with Tacrolimus in Transplant Recipient

### Clinical Image
![Diagram illustrating CYP3A4 inhibition by ritonavir leading to elevated tacrolimus levels](case_04_image.jpg)
*Source: [Wikipedia - Nirmatrelvir/ritonavir](https://en.wikipedia.org/wiki/Nirmatrelvir/ritonavir) - CC BY-SA 4.0*

### Case Presentation
A 62-year-old female with a history of renal transplantation 3 years ago, maintained on tacrolimus 4 mg twice daily (most recent trough level 7.2 ng/mL), mycophenolate mofetil 1000 mg twice daily, and prednisone 5 mg daily, develops mild COVID-19 symptoms including sore throat, rhinorrhea, and low-grade fever. She tests positive for SARS-CoV-2 by rapid antigen within 3 days of symptom onset. Her primary care physician prescribes nirmatrelvir/ritonavir (Paxlovid) 300 mg/300 mg twice daily for 5 days without consulting her transplant team. She continues her usual tacrolimus dose. By day 3 of Paxlovid therapy, she presents to the emergency department with tremor, headache, nausea, and decreased urine output. Vital signs show BP 162/98 mmHg, HR 88 bpm, and she is afebrile. Laboratory studies reveal serum creatinine 3.4 mg/dL (baseline 1.2), BUN 48 mg/dL, potassium 5.8 mEq/L, magnesium 1.2 mg/dL, glucose 198 mg/dL, and a stat tacrolimus trough level of 68 ng/mL (toxic; therapeutic range 5-15 ng/mL). The tacrolimus and mycophenolate are immediately held. She is admitted for continuous cardiac monitoring given hyperkalemia, treated with calcium gluconate, insulin/dextrose, and sodium polystyrene sulfonate. Tacrolimus levels are monitored every 12 hours and gradually decline over 5 days due to the drug's long half-life when CYP3A4 is inhibited. Her creatinine returns to 1.5 mg/dL by hospital day 7, and immunosuppression is carefully reintroduced at reduced doses.

### Key Learning Points
- Ritonavir, the pharmacokinetic booster in Paxlovid, is a potent irreversible inhibitor of CYP3A4 and P-glycoprotein; tacrolimus is almost exclusively metabolized by CYP3A4, and co-administration can increase tacrolimus levels 5- to 70-fold within 2-3 days
- In transplant recipients requiring Paxlovid, the recommended approach is to hold tacrolimus entirely for the 5-day treatment course, reduce cyclosporine doses by 80%, and monitor drug levels daily with plans for dose re-titration after ritonavir clearance (half-life approximately 3-5 hours, but CYP3A4 recovery takes 3-5 days due to mechanism-based inhibition)
- Calcineurin inhibitor toxicity manifests as acute nephrotoxicity (afferent arteriolar vasoconstriction), neurotoxicity (tremor, posterior reversible encephalopathy syndrome), electrolyte derangements (hyperkalemia, hypomagnesemia), and new-onset diabetes
- Immunocompromised patients are at higher risk for severe COVID-19 and prolonged viral shedding, yet drug interaction management must be carefully coordinated between infectious disease and transplant teams before initiating Paxlovid

---

## Case 5: Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)

### Clinical Image
![MR venography demonstrating cerebral venous sinus thrombosis with superior sagittal sinus and transverse sinus occlusion](case_05_image.jpg)
*Source: [Wikipedia - Cerebral venous sinus thrombosis](https://en.wikipedia.org/wiki/Cerebral_venous_sinus_thrombosis) - CC BY-SA 4.0*

### Case Presentation
A 34-year-old female presents to the emergency department with 3 days of progressively worsening thunderclap headache, photophobia, nausea, and vomiting beginning 11 days after receiving her first dose of an adenoviral vector COVID-19 vaccine (Ad26.COV2.S). She has no prior history of heparin exposure, thrombophilia, or oral contraceptive use. On examination, she is alert but appears uncomfortable, with papilledema on fundoscopic examination and no focal neurological deficits initially. Vital signs show HR 96 bpm, BP 148/92 mmHg, and temperature 37.2C. Initial laboratory results reveal platelet count 38 x 10^9/L (normal 150-400), D-dimer >35 mcg/mL FEU (markedly elevated), fibrinogen 120 mg/dL (low-normal), PT/INR and aPTT mildly prolonged. CT head without contrast shows a hyperdense superior sagittal sinus. CT venography confirms extensive thrombosis of the superior sagittal sinus and left transverse sinus with surrounding cerebral edema. An anti-PF4 ELISA is sent and returns strongly positive (OD 3.2), with confirmatory positive PF4-dependent platelet activation assay (functional HIPA test). Heparin is strictly avoided. She is started on argatroban IV infusion (non-heparin anticoagulant) titrated to aPTT 1.5-3x baseline, and receives IVIG 1 g/kg daily for 2 days. Platelet count recovers to 124 x 10^9/L by day 5. She is transitioned to oral rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg daily. Serial imaging at 3 months shows partial recanalization.

### Key Learning Points
- VITT is caused by adenoviral vector vaccine components (or adenoviral DNA-PF4 complexes) triggering formation of high-titer IgG antibodies against platelet factor 4 (PF4) that activate platelets via FcgammaRIIA receptors, mechanistically analogous to autoimmune heparin-induced thrombocytopenia (aHIT) but occurring without prior heparin exposure
- The classic VITT presentation occurs 4-28 days post-vaccination with thrombosis at unusual sites (cerebral venous sinuses, splanchnic veins, adrenal veins) combined with thrombocytopenia, markedly elevated D-dimer, and low-to-normal fibrinogen
- Heparin must be strictly avoided in VITT because anti-PF4 antibodies can be further activated by heparin-PF4 complexes; alternative anticoagulants include argatroban (direct thrombin inhibitor), fondaparinux, or direct oral anticoagulants
- IVIG at 1 g/kg for 2 days blocks FcgammaRIIA-mediated platelet activation by saturating Fc receptors and is a critical adjunctive therapy alongside non-heparin anticoagulation

---

## Case 6: Long COVID with Postural Orthostatic Tachycardia Syndrome (POTS)

### Clinical Image
![Tilt table testing results showing excessive heart rate increase upon standing consistent with POTS](case_06_image.jpg)
*Source: [Wikipedia - Postural orthostatic tachycardia syndrome](https://en.wikipedia.org/wiki/Postural_orthostatic_tachycardia_syndrome) - CC BY-SA 4.0*

### Case Presentation
A 29-year-old previously healthy female graduate student presents to an autonomic disorders clinic 4 months after a mild COVID-19 infection that did not require hospitalization. She reports persistent debilitating fatigue, brain fog with impaired concentration, exercise intolerance with post-exertional malaise lasting 24-48 hours after minimal activity, palpitations, lightheadedness upon standing, and intermittent pre-syncope. She has been unable to attend classes or perform her research duties. She denies chest pain, weight loss, or joint symptoms. On examination, supine HR is 68 bpm and BP is 118/72 mmHg. Upon active standing, HR increases to 112 bpm within 3 minutes (delta HR +44 bpm) with BP 114/78 mmHg (no orthostatic hypotension). She becomes visibly diaphoretic and reports lightheadedness. A 10-minute active standing test confirms sustained tachycardia with HR peaking at 126 bpm. Head-up tilt table testing reproduces symptoms with HR increase from 64 to 118 bpm within 5 minutes without significant blood pressure drop. Norepinephrine levels drawn supine (280 pg/mL) and upright (890 pg/mL; elevated) suggest a hyperadrenergic component. Autoimmune panel reveals positive anti-ganglionic acetylcholine receptor antibodies at low titer. CBC, TSH, cortisol, echocardiography, and Holter monitoring are unremarkable. She is started on oral salt supplementation (6-8 g sodium/day), compression stockings (30-40 mmHg), a graduated recumbent exercise program, and propranolol 10 mg three times daily, with significant symptomatic improvement over 3 months.

### Key Learning Points
- Post-acute sequelae of SARS-CoV-2 (PASC/Long COVID) affects 10-30% of patients regardless of acute disease severity; dysautonomia (particularly POTS) is a common manifestation, defined as a sustained HR increase of 30 or more bpm within 10 minutes of standing (or HR >120 bpm) without orthostatic hypotension
- Proposed mechanisms for post-COVID POTS include autoantibody-mediated autonomic neuropathy (anti-ganglionic AChR, anti-adrenergic receptor antibodies), persistent viral-induced small fiber neuropathy affecting sympathetic postganglionic fibers, brainstem neuroinflammation, and hypovolemia from impaired renin-angiotensin-aldosterone signaling
- Post-exertional malaise (PEM) in Long COVID shares pathophysiological features with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), potentially driven by mitochondrial dysfunction, impaired oxygen extraction, and microclot-mediated perfusion deficits
- Management is multimodal: volume expansion (salt, fluids), physical counter-maneuvers, graduated recumbent exercise (avoiding upright exertion initially), and pharmacotherapy tailored to the subtype -- beta-blockers for hyperadrenergic POTS, midodrine or fludrocortisone for neuropathic/hypovolemic subtypes

---

## Case 7: COVID-19-Associated Pulmonary Aspergillosis (CAPA)

### Clinical Image
![CT chest showing cavitary lesion with air crescent sign in the right upper lobe and surrounding ground-glass opacity](case_07_image.jpg)
*Source: [Wikipedia - Aspergillosis](https://en.wikipedia.org/wiki/Aspergillosis) - CC BY-SA 4.0*

### Case Presentation
A 66-year-old male with COPD (FEV1 48% predicted) and severe COVID-19 pneumonia has been mechanically ventilated in the ICU for 14 days. He received dexamethasone 6 mg daily for 10 days and an 8 mg/kg dose of tocilizumab on day 3 of admission. Despite initial improvement in oxygenation, he develops recurrent fevers to 39.6C, progressive leukocytosis (WBC 18.4 x 10^9/L), and worsening hypoxia requiring increasing ventilator support (FiO2 escalated from 0.40 to 0.70 over 72 hours). Tracheal aspirate cultures grow mold, and bronchoscopy with bronchoalveolar lavage (BAL) is performed. BAL fluid reveals septate hyphae with acute-angle (45-degree) dichotomous branching on GMS stain, consistent with Aspergillus species. BAL galactomannan index is 4.8 (positive >1.0), and serum galactomannan is 1.6. BAL culture confirms Aspergillus fumigatus with MIC to voriconazole of 0.5 mcg/mL (susceptible). Repeat CT chest demonstrates a new 3.2-cm cavitary lesion in the right upper lobe with surrounding ground-glass halo sign, along with nodular infiltrates in the left lower lobe. He is started on IV voriconazole 6 mg/kg every 12 hours for 2 loading doses then 4 mg/kg every 12 hours with therapeutic drug monitoring (target trough 1-5.5 mcg/mL). Despite antifungal therapy, his course is complicated by progressive respiratory failure, and he expires on ICU day 28.

### Key Learning Points
- CAPA occurs in 10-30% of mechanically ventilated COVID-19 patients and carries mortality rates exceeding 50%; risk factors include prolonged corticosteroid use, IL-6 receptor blockade, structural lung disease (COPD, prior TB), and diabetes mellitus
- SARS-CoV-2 impairs pulmonary antifungal defenses through multiple mechanisms: viral-induced epithelial damage exposes the basement membrane to Aspergillus conidia, corticosteroids and tocilizumab suppress alveolar macrophage fungicidal activity and neutrophil recruitment, and COVID-19-associated lymphopenia reduces Th1/Th17 responses critical for anti-Aspergillus immunity
- Diagnosis of CAPA requires a high index of suspicion; serum galactomannan has poor sensitivity (approximately 30%) in non-neutropenic patients, making BAL galactomannan (sensitivity approximately 75-80%) and BAL culture essential -- the threshold for positivity in BAL galactomannan in CAPA is an index of 1.0 or greater
- Voriconazole is first-line therapy for invasive pulmonary aspergillosis and requires therapeutic drug monitoring due to nonlinear pharmacokinetics, CYP2C19 polymorphism-dependent metabolism, and potential hepatotoxicity; isavuconazole is an alternative with fewer drug interactions and no need for cyclodextrin vehicle (relevant in renal impairment)

---

## Case 8: Acute Ischemic Stroke in a Young Patient with COVID-19

### Clinical Image
![CT angiography showing large vessel occlusion of the left middle cerebral artery M1 segment](case_08_image.jpg)
*Source: [Wikipedia - Ischemic stroke](https://en.wikipedia.org/wiki/Stroke) - Public Domain*

### Case Presentation
A 38-year-old male with no significant past medical history is brought to the emergency department by ambulance after his wife witnessed sudden onset of right-sided weakness, facial droop, and inability to speak at 07:15. EMS reports symptom onset was approximately 90 minutes prior to arrival. He had tested positive for SARS-CoV-2 5 days ago with mild fever and myalgias. He is a non-smoker, takes no medications, and has no family history of stroke or coagulopathy. On examination, BP is 156/92 mmHg, HR 102 bpm, SpO2 94% on room air, and temperature 38.1C. Neurological assessment reveals global aphasia, right hemianopia, right hemiplegia with forced left gaze deviation, and a National Institutes of Health Stroke Scale (NIHSS) score of 19. Non-contrast CT head shows no hemorrhage with an ASPECTS score of 8. CT angiography demonstrates complete occlusion of the left middle cerebral artery (MCA) at the M1 segment with good collateral circulation. CT perfusion reveals a large penumbral mismatch (ischemic core 18 mL, penumbra 124 mL). IV alteplase 0.9 mg/kg is administered (10% bolus, 90% over 60 minutes) within the 4.5-hour window. He undergoes emergent mechanical thrombectomy with successful recanalization (TICI 2b/3) at 3 hours post-onset. Retrieved thrombus histopathology reveals a platelet-rich thrombus with abundant NET-laden neutrophils, consistent with immunothrombosis. Post-procedure workup reveals D-dimer 8.4 mcg/mL FEU, fibrinogen 580 mg/dL, anticardiolipin IgM positive (transient), and lupus anticoagulant positive. He is started on therapeutic enoxaparin 1 mg/kg subcutaneously every 12 hours. At discharge on day 8, his NIHSS has improved to 4, and repeat antiphospholipid antibody testing at 12 weeks is negative, consistent with transient infection-associated antiphospholipid antibodies.

### Key Learning Points
- COVID-19 increases the risk of acute ischemic stroke 3- to 8-fold, even in young patients without traditional cardiovascular risk factors; mechanisms include endotheliitis from direct viral invasion of endothelial cells, hypercoagulability with elevated von Willebrand factor and factor VIII, NET-mediated immunothrombosis, and cardioembolism from COVID-associated myocarditis or atrial fibrillation
- Large vessel occlusion (LVO) strokes in COVID-19 patients disproportionately affect younger patients and often involve multiple vascular territories simultaneously; thrombus histopathology characteristically shows NET-rich, platelet-rich composition distinct from typical atherothrombotic clots
- Transient antiphospholipid antibodies (anticardiolipin, anti-beta2-glycoprotein I, lupus anticoagulant) are found in 30-50% of hospitalized COVID-19 patients and contribute to thrombotic risk through complement activation and endothelial cell activation; persistent positivity at 12 weeks is required to diagnose true antiphospholipid syndrome
- Acute stroke management in COVID-19 follows standard guidelines (IV thrombolysis within 4.5 hours, mechanical thrombectomy for LVO within 24 hours with favorable perfusion imaging), but post-stroke anticoagulation decisions must weigh the transient hypercoagulable state against hemorrhagic transformation risk